NCT05389449: A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
- State
- Under way
- Phase
- Phase 3
- People
- 80 taking part
- Started
- 28 Oct 2022
- Primary completion
- 24 Aug 2026
- Arms
- Danicopan
- Results
- None posted
- 25 May 2022: Trial registered
- 28 Oct 2022: Trial started